🚀 VC round data is live in beta, check it out!
Sight Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sight Sciences and similar public comparables like Median Technologies, OraSure, Utah Medical, SmartVest and more.
Sight Sciences Overview
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Founded
2010
HQ
Employees
216
Website
Financials (LTM)
EV
$170M
Sight Sciences Financials
Sight Sciences reported last 12-month revenue of $80M and negative EBITDA of ($25M).
In the same LTM period, Sight Sciences generated $68M in gross profit, ($25M) in EBITDA losses, and had net loss of ($37M).
Revenue (LTM)
Sight Sciences P&L
In the most recent fiscal year, Sight Sciences reported revenue of $77M and EBITDA of ($26M).
Sight Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $80M | XXX | $77M | XXX | XXX | XXX |
| Gross Profit | $68M | XXX | $67M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | ($25M) | XXX | ($26M) | XXX | XXX | XXX |
| EBITDA Margin | (32%) | XXX | (34%) | XXX | XXX | XXX |
| EBIT Margin | (44%) | XXX | (48%) | XXX | XXX | XXX |
| Net Profit | ($37M) | XXX | ($38M) | XXX | XXX | XXX |
| Net Margin | (46%) | XXX | (50%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sight Sciences Stock Performance
Sight Sciences has current market cap of $221M, and enterprise value of $170M.
Market Cap Evolution
Sight Sciences' stock price is $4.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $170M | $221M | 0.0% | XXX | XXX | XXX | $-0.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSight Sciences Valuation Multiples
Sight Sciences trades at 2.1x EV/Revenue multiple, and (6.7x) EV/EBITDA.
EV / Revenue (LTM)
Sight Sciences Financial Valuation Multiples
As of April 19, 2026, Sight Sciences has market cap of $221M and EV of $170M.
Equity research analysts estimate Sight Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sight Sciences has a P/E ratio of (6.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $221M | XXX | $221M | XXX | XXX | XXX |
| EV (current) | $170M | XXX | $170M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | (6.7x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/EBIT | (4.8x) | XXX | (4.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | 2.5x | XXX | XXX | XXX |
| P/E | (6.0x) | XXX | (5.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sight Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sight Sciences Margins & Growth Rates
Sight Sciences' revenue in the last 12 month grew by 10%.
Sight Sciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Sight Sciences' rule of 40 is (18%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sight Sciences' rule of X is (4%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sight Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | (32%) | XXX | (34%) | XXX | XXX | XXX |
| EBITDA Growth | (12%) | XXX | (12%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (18%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (4%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 134% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sight Sciences Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sight Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Median Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| OraSure | XXX | XXX | XXX | XXX | XXX | XXX |
| Utah Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| Anika Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sight Sciences M&A Activity
Sight Sciences acquired XXX companies to date.
Last acquisition by Sight Sciences was on XXXXXXXX, XXXXX. Sight Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sight Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSight Sciences Investment Activity
Sight Sciences invested in XXX companies to date.
Sight Sciences made its latest investment on XXXXXXXX, XXXXX. Sight Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sight Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sight Sciences
| When was Sight Sciences founded? | Sight Sciences was founded in 2010. |
| Where is Sight Sciences headquartered? | Sight Sciences is headquartered in United States. |
| How many employees does Sight Sciences have? | As of today, Sight Sciences has over 216 employees. |
| Who is the CEO of Sight Sciences? | Sight Sciences' CEO is Paul Badawi. |
| Is Sight Sciences publicly listed? | Yes, Sight Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Sight Sciences? | Sight Sciences trades under SGHT ticker. |
| When did Sight Sciences go public? | Sight Sciences went public in 2021. |
| Who are competitors of Sight Sciences? | Sight Sciences main competitors are Median Technologies, OraSure, Utah Medical, SmartVest. |
| What is the current market cap of Sight Sciences? | Sight Sciences' current market cap is $221M. |
| What is the current revenue of Sight Sciences? | Sight Sciences' last 12 months revenue is $80M. |
| What is the current revenue growth of Sight Sciences? | Sight Sciences revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Sight Sciences? | Current revenue multiple of Sight Sciences is 2.1x. |
| Is Sight Sciences profitable? | No, Sight Sciences is not profitable. |
| What is the current EBITDA of Sight Sciences? | Sight Sciences has negative EBITDA and is not profitable. |
| What is Sight Sciences' EBITDA margin? | Sight Sciences' last 12 months EBITDA margin is (32%). |
| What is the current EV/EBITDA multiple of Sight Sciences? | Current EBITDA multiple of Sight Sciences is (6.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.